Pegdinetanib

Pegdinetanib (USAN; planned trade name Angiocept) is an investigational anti-cancer drug that acts as a selective antagonist of vascular endothelial growth factor receptor 2 (VEGFR-2), hindering vascularization of tumors. It is a genetically engineered peptide derivative based on the monobody technology, and is being developed by Adnexus.[1][2]

Pegdinetanib
Clinical data
Trade namesAngiocept
Other namesCT-322; BMS-844203
Routes of
administration		Intravenous
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC468H729N125O139S (un-PEGylated peptide)
Molar mass10362.78 g·mol−1

The drug has entered Phase II clinical trials investigating the treatment of glioblastoma in October 2007.[3][4] As of August 2012, it is also in Phase II trials for the treatment of non-small cell lung cancer[5] and colorectal cancer.[6]

Chemical structure

Pegdinetanib is a peptide consisting of 94 amino acids, with cysteine number 93 carrying a doubly methoxy-PEGylated maleimide derivative with a molecular mass of 40 kDa.[7]

gollark: This would miss unusual meanings, but we can't do much about that without accursed ML things of some sort.
gollark: The formulae seem to be based on word length and other such badness, but we have computers now, so a lookup table for word weirdness is very practical.
gollark: I'd probably try and do it based on grammatical nesting level and commonness of words.
gollark: ddg! Analytic vs infinitely differentiable
gollark: It can only index finitely many things on that HDD unless you do weird indirected addressing.

References
  1. Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, et al. (January 2011). "Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin". Clinical Cancer Research. 17 (2): 363–71. doi:10.1158/1078-0432.CCR-10-1411. PMID 21224368.
  2. Mamluk R, Carvajal IM, Morse BA, Wong H, Abramowitz J, Aslanian S, et al. (2010). "Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2". mAbs. 2 (2): 199–208. doi:10.4161/mabs.2.2.11304. PMC 2840239. PMID 20190562.
  3. Clinical trial number NCT00562419 for "CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan" at ClinicalTrials.gov
  4. Bloom L, Calabro V (October 2009). "FN3: a new protein scaffold reaches the clinic". Drug Discovery Today. 14 (19–20): 949–55. doi:10.1016/j.drudis.2009.06.007. PMID 19576999.
  5. Clinical trial number NCT00850577 for "Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer" at ClinicalTrials.gov
  6. Clinical trial number NCT00851045 for "Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer" at ClinicalTrials.gov
  7. Statement On A Nonproprietary Name Adopted By The USAN Council: Pegdinetanib
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.